Diagnostics
distinguish Alzheimer’s disease from healthy controls with high accuracy.
Patients with cognitive concerns can undergo a comprehensive evaluation that includes their clinical history, neurological examination and cognitive testing, routine laboratories and a brain MRI, for example. But for patients seeking a more certain diagnosis, explains Schindler, “or who wish to be considered for anti- amyloid treatments, we perform biomarker testing for Alzheimer’s disease”, she adds. “Although not widely available or reimbursed yet in most health care systems, high-performing blood tests are close to being implemented,” adds Mattsson-Carlgren.
Innovating imaging
While blood-based tests are gaining traction, imaging technologies continue to evolve. Innovations in PET imaging, such as tau-specific tracers, offer more accurate insight into the course of the disease. “Tau PET and Amyloid PET remain highly valuable to identify and characterise Alzheimer’s disease, including the spread of pathology over the brain, even at stages where fluid biomarkers have reached their ceilings,” explains Mattsson-Carlgren. Additionally, machine learning algorithms are being integrated with imaging to enhance diagnostic accuracy and predict patient outcomes. Artificial intelligence (AI) is also transforming MRI analysis. AI algorithms can identify subtle brain changes associated with Alzheimer’s, such as hippocampal atrophy, long before these changes are visible to the human eye. These advancements not only improve diagnostic precision but also enable personalised treatment plans. One of the mainstays of Alzheimer’s research has always been genetic testing. Mutations in genes including APP, PSEN1 and PSEN2 are linked to early- onset familial Alzheimer’s disease, while the APOE-4 allele increases the risk of late-onset Alzheimer’s. Recent advancements have made genetic testing more accessible, allowing anyone with a family history of Alzheimer’s to assess their risk. However, “a positive result does not guarantee disease onset but highlights the importance of regular monitoring and preventive measures,” says Mattsson-Carlgren. In response to these innovations, diagnostic guidelines for Alzheimer’s have undergone significant revisions. The International Working Group (IWG) and the National Institute on Aging-Alzheimer’s Association (NIA-AA) now emphasise a biomarker-based approach. The updated criteria include individuals with normal cognition who test positive for biomarkers, recognising that Alzheimer’s pathology begins years before symptoms manifest. The WHO has also published preferred product characteristics for blood tests, aiming to standardise their development and ensure global accessibility. These guidelines prioritise tests that are affordable, accurate, and adaptable to diverse healthcare settings.
Practical Patient Care /
www.practical-patient-care.com Giving patients a chance
Early diagnosis is critical for optimising Alzheimer’s care. Identifying the disease in its preclinical stage enables patients to access emerging therapies targeting amyloid-beta and tau proteins, implement lifestyle changes such as exercise and cognitive training that may delay disease progression, and participate in clinical trials, contributing to research and potentially benefiting from cutting-edge treatments. Blood-based biomarker tests are particularly transformative in this regard. Their simplicity and scalability make routine screening feasible, paving the way for population-wide early detection programmes. “With blood biomarkers of amyloid and tau, more accurate diagnosis can suddenly be possible also in settings without access to CSF or PET, such as primary care contexts, or low-resource contexts,” says Mattsson-Carlgren.
Despite these advancements, several challenges remain. Blood-based tests must undergo rigorous validation to ensure their reliability across diverse populations. While less expensive than imaging, these tests must be affordable and integrated into public health systems to achieve widespread impact. Given the need to help patients and their families and the lack of curative treatments, early diagnosis also presents an ethical concern regarding disclosure. Looking ahead, researchers are exploring novel biomarkers, such as inflammatory markers and synaptic proteins, to capture the full spectrum of Alzheimer’s pathology. Advances in multi-omics – integrating genomics, proteomics and metabolomics – hold promise for uncovering new diagnostic targets. Mattsson-Carlgren foresees “the widespread availability of high-performing blood biomarkers, coupled with strategic PET or CSF in those with indeterminable risk based on blood biomarkers, and coupled with decisions to start, stop, restart, or change treatment strategies”. Schindler is hopeful, too, for treatments that can forestall cognitive decline in individuals with biomarkers of Alzheimer’s disease. “I expect that we will be able to use blood biomarker tests to predict approximately when cognitively normal individuals are likely to develop symptoms of Alzheimer’s disease,” she adds. The field of Alzheimer’s diagnosis is undergoing a seismic change. These developments, which range from sophisticated biomarker tests to conventional cognitive evaluations and imaging, innovations offer unprecedented opportunities for early detection and intervention. The future of Alzheimer’s care appears to be more promising than ever as specialists like Mattsson-Carlgren and Schindler continue to push the limits of research. By embracing these advancements and addressing the accompanying challenges, a new era of precision medicine is on the cusp of transforming the diagnosis and treatment of Alzheimer’s.
9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45
